Concepts (215)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cocaine | 42 | 2020 | 256 | 8.840 |
Why?
|
| Cocaine-Related Disorders | 18 | 2016 | 99 | 4.770 |
Why?
|
| Dopamine Uptake Inhibitors | 18 | 2019 | 117 | 3.800 |
Why?
|
| Self Administration | 36 | 2020 | 297 | 2.940 |
Why?
|
| Receptors, Dopamine D2 | 10 | 2017 | 79 | 2.480 |
Why?
|
| Choice Behavior | 10 | 2020 | 87 | 2.450 |
Why?
|
| Dose-Response Relationship, Drug | 31 | 2020 | 633 | 2.000 |
Why?
|
| Receptors, Dopamine D3 | 6 | 2017 | 33 | 1.900 |
Why?
|
| Animals | 66 | 2020 | 7541 | 1.900 |
Why?
|
| Macaca mulatta | 29 | 2020 | 305 | 1.890 |
Why?
|
| Feeding Behavior | 7 | 2020 | 161 | 1.780 |
Why?
|
| Macaca fascicularis | 22 | 2020 | 434 | 1.610 |
Why?
|
| Social Dominance | 5 | 2017 | 18 | 1.570 |
Why?
|
| Conditioning, Operant | 10 | 2011 | 88 | 1.450 |
Why?
|
| Hierarchy, Social | 6 | 2017 | 24 | 1.440 |
Why?
|
| Ethanol | 3 | 2017 | 187 | 1.390 |
Why?
|
| Behavior, Animal | 12 | 2010 | 250 | 1.380 |
Why?
|
| Central Nervous System Stimulants | 4 | 2016 | 76 | 1.360 |
Why?
|
| Reinforcement Schedule | 12 | 2016 | 57 | 1.180 |
Why?
|
| Dopamine Agents | 3 | 2015 | 19 | 1.150 |
Why?
|
| Menstrual Cycle | 4 | 2018 | 61 | 1.080 |
Why?
|
| Alcohol Drinking | 2 | 2019 | 249 | 1.070 |
Why?
|
| Receptors, Opioid, mu | 4 | 2020 | 31 | 1.030 |
Why?
|
| Male | 51 | 2020 | 19165 | 1.010 |
Why?
|
| Positron-Emission Tomography | 11 | 2020 | 163 | 0.960 |
Why?
|
| Yawning | 4 | 2017 | 8 | 0.870 |
Why?
|
| Dextroamphetamine | 3 | 2013 | 10 | 0.840 |
Why?
|
| Buprenorphine | 2 | 2019 | 13 | 0.800 |
Why?
|
| Caudate Nucleus | 5 | 2017 | 25 | 0.740 |
Why?
|
| Guanfacine | 1 | 2020 | 5 | 0.730 |
Why?
|
| Dopamine Antagonists | 4 | 2017 | 22 | 0.720 |
Why?
|
| Housing, Animal | 5 | 2015 | 23 | 0.710 |
Why?
|
| Morpholines | 2 | 2020 | 37 | 0.710 |
Why?
|
| Clonidine | 1 | 2020 | 62 | 0.700 |
Why?
|
| Sex Characteristics | 2 | 2020 | 173 | 0.690 |
Why?
|
| Receptors, Metabotropic Glutamate | 1 | 2019 | 24 | 0.680 |
Why?
|
| Dopamine Agonists | 5 | 2015 | 28 | 0.680 |
Why?
|
| Amino Acids | 1 | 2019 | 46 | 0.680 |
Why?
|
| Receptors, Opioid | 1 | 2019 | 12 | 0.670 |
Why?
|
| Dopamine | 4 | 2015 | 232 | 0.620 |
Why?
|
| Discrimination Learning | 4 | 2011 | 19 | 0.620 |
Why?
|
| Brain | 7 | 2020 | 951 | 0.610 |
Why?
|
| Substance-Related Disorders | 4 | 2017 | 128 | 0.600 |
Why?
|
| Disease Models, Animal | 8 | 2017 | 1022 | 0.580 |
Why?
|
| Drug Discovery | 2 | 2016 | 32 | 0.570 |
Why?
|
| Norepinephrine | 2 | 2015 | 77 | 0.540 |
Why?
|
| Piperazines | 4 | 2012 | 54 | 0.530 |
Why?
|
| Learning | 3 | 2015 | 79 | 0.520 |
Why?
|
| Buspirone | 1 | 2015 | 3 | 0.500 |
Why?
|
| Phenmetrazine | 1 | 2015 | 4 | 0.500 |
Why?
|
| Methamphetamine | 3 | 2014 | 17 | 0.500 |
Why?
|
| Benzamides | 6 | 2017 | 50 | 0.490 |
Why?
|
| Methylphenidate | 2 | 2013 | 36 | 0.480 |
Why?
|
| Putamen | 5 | 2017 | 25 | 0.480 |
Why?
|
| Memory, Short-Term | 1 | 2015 | 60 | 0.480 |
Why?
|
| Cognition | 2 | 2015 | 555 | 0.460 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2016 | 510 | 0.460 |
Why?
|
| Eating | 3 | 2019 | 74 | 0.440 |
Why?
|
| Stress, Psychological | 3 | 2012 | 221 | 0.440 |
Why?
|
| Quinolones | 1 | 2012 | 7 | 0.430 |
Why?
|
| Primates | 8 | 2018 | 108 | 0.400 |
Why?
|
| Behavior, Addictive | 3 | 2007 | 32 | 0.400 |
Why?
|
| Carboxylic Ester Hydrolases | 1 | 2011 | 3 | 0.400 |
Why?
|
| N-Methyl-3,4-methylenedioxyamphetamine | 5 | 2011 | 14 | 0.400 |
Why?
|
| Analgesics, Opioid | 3 | 2019 | 232 | 0.390 |
Why?
|
| Exploratory Behavior | 2 | 2010 | 30 | 0.370 |
Why?
|
| Tropanes | 1 | 2010 | 9 | 0.360 |
Why?
|
| Vaccination | 1 | 2011 | 138 | 0.360 |
Why?
|
| Reward | 1 | 2010 | 64 | 0.350 |
Why?
|
| Drug Interactions | 6 | 2015 | 78 | 0.350 |
Why?
|
| Hydrocortisone | 2 | 2009 | 57 | 0.340 |
Why?
|
| Serotonin | 5 | 2008 | 37 | 0.340 |
Why?
|
| Raclopride | 2 | 2005 | 8 | 0.330 |
Why?
|
| Receptors, Dopamine D1 | 2 | 2010 | 19 | 0.320 |
Why?
|
| Saimiri | 8 | 2017 | 8 | 0.320 |
Why?
|
| Testosterone | 1 | 2009 | 48 | 0.320 |
Why?
|
| Corpus Striatum | 2 | 2005 | 60 | 0.320 |
Why?
|
| Receptors, Dopamine | 3 | 2015 | 20 | 0.310 |
Why?
|
| Follicular Phase | 3 | 2018 | 11 | 0.270 |
Why?
|
| Pyridines | 2 | 2017 | 76 | 0.270 |
Why?
|
| Quinpirole | 3 | 2015 | 15 | 0.270 |
Why?
|
| Luteal Phase | 3 | 2018 | 29 | 0.270 |
Why?
|
| Time Factors | 8 | 2011 | 2149 | 0.260 |
Why?
|
| 8-Hydroxy-2-(di-n-propylamino)tetralin | 1 | 2005 | 1 | 0.260 |
Why?
|
| Receptor, Serotonin, 5-HT1A | 1 | 2005 | 4 | 0.250 |
Why?
|
| Catheters, Indwelling | 2 | 2016 | 43 | 0.250 |
Why?
|
| Administration, Oral | 2 | 2016 | 187 | 0.250 |
Why?
|
| Membrane Transport Modulators | 1 | 2004 | 4 | 0.240 |
Why?
|
| Social Behavior | 2 | 2016 | 65 | 0.240 |
Why?
|
| Receptors, Serotonin | 2 | 2002 | 7 | 0.240 |
Why?
|
| Membrane Transport Proteins | 1 | 2004 | 35 | 0.240 |
Why?
|
| Injections, Intravenous | 4 | 2013 | 78 | 0.240 |
Why?
|
| Membrane Glycoproteins | 1 | 2004 | 101 | 0.230 |
Why?
|
| Nerve Tissue Proteins | 1 | 2004 | 120 | 0.230 |
Why?
|
| Food | 3 | 2013 | 43 | 0.220 |
Why?
|
| Female | 12 | 2020 | 19959 | 0.220 |
Why?
|
| Piperidines | 4 | 2010 | 118 | 0.210 |
Why?
|
| Alanine | 1 | 2002 | 27 | 0.200 |
Why?
|
| Brain Chemistry | 1 | 2002 | 29 | 0.200 |
Why?
|
| Progesterone | 2 | 2015 | 101 | 0.200 |
Why?
|
| Opioid Peptides | 2 | 2018 | 14 | 0.200 |
Why?
|
| Drug Administration Schedule | 4 | 2020 | 276 | 0.190 |
Why?
|
| Dominance-Subordination | 2 | 2012 | 16 | 0.190 |
Why?
|
| Serotonin Plasma Membrane Transport Proteins | 3 | 2011 | 16 | 0.190 |
Why?
|
| Serotonin Antagonists | 1 | 2000 | 5 | 0.190 |
Why?
|
| Aza Compounds | 1 | 2000 | 3 | 0.190 |
Why?
|
| Spiro Compounds | 1 | 2000 | 2 | 0.190 |
Why?
|
| Urea | 1 | 2020 | 37 | 0.180 |
Why?
|
| Thiophenes | 1 | 2020 | 23 | 0.180 |
Why?
|
| Ligands | 3 | 2018 | 81 | 0.180 |
Why?
|
| Carbon Radioisotopes | 1 | 2020 | 24 | 0.180 |
Why?
|
| Pruritus | 1 | 2020 | 47 | 0.180 |
Why?
|
| Microtubules | 1 | 2020 | 23 | 0.180 |
Why?
|
| Quinazolines | 1 | 2020 | 38 | 0.180 |
Why?
|
| Benzazepines | 3 | 2011 | 21 | 0.180 |
Why?
|
| Drug Tolerance | 2 | 2019 | 32 | 0.170 |
Why?
|
| Hallucinogens | 3 | 2008 | 12 | 0.170 |
Why?
|
| Radiopharmaceuticals | 1 | 2020 | 93 | 0.170 |
Why?
|
| Analgesics | 1 | 2020 | 109 | 0.170 |
Why?
|
| Prenatal Exposure Delayed Effects | 2 | 2010 | 92 | 0.170 |
Why?
|
| Azabicyclo Compounds | 1 | 2019 | 7 | 0.170 |
Why?
|
| Naltrexone | 1 | 2019 | 18 | 0.170 |
Why?
|
| Microdialysis | 3 | 2004 | 34 | 0.150 |
Why?
|
| Dopamine Plasma Membrane Transport Proteins | 2 | 2012 | 97 | 0.150 |
Why?
|
| Analysis of Variance | 4 | 2012 | 463 | 0.150 |
Why?
|
| Temperature | 2 | 2007 | 55 | 0.150 |
Why?
|
| Motivation | 2 | 2008 | 112 | 0.140 |
Why?
|
| Social Environment | 2 | 2008 | 79 | 0.140 |
Why?
|
| Infusions, Intravenous | 2 | 2010 | 100 | 0.140 |
Why?
|
| Blood Chemical Analysis | 1 | 2016 | 22 | 0.130 |
Why?
|
| Recurrence | 2 | 2015 | 263 | 0.130 |
Why?
|
| Models, Animal | 2 | 2014 | 169 | 0.130 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2009 | 1328 | 0.120 |
Why?
|
| Estradiol | 1 | 2015 | 136 | 0.120 |
Why?
|
| Pain | 1 | 2016 | 288 | 0.120 |
Why?
|
| Humans | 9 | 2017 | 32005 | 0.110 |
Why?
|
| Radioligand Assay | 2 | 2010 | 20 | 0.110 |
Why?
|
| Fluorine Radioisotopes | 2 | 2010 | 19 | 0.110 |
Why?
|
| Drug Partial Agonism | 1 | 2012 | 2 | 0.110 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2015 | 743 | 0.110 |
Why?
|
| Adrenocorticotropic Hormone | 2 | 2009 | 19 | 0.100 |
Why?
|
| Dexamethasone | 2 | 2009 | 45 | 0.100 |
Why?
|
| Quinoxalines | 1 | 2011 | 13 | 0.100 |
Why?
|
| Nicotinic Agonists | 1 | 2011 | 39 | 0.100 |
Why?
|
| Rats | 1 | 2015 | 1595 | 0.090 |
Why?
|
| Pregnancy, Animal | 1 | 2010 | 19 | 0.090 |
Why?
|
| Haplorhini | 2 | 2011 | 68 | 0.090 |
Why?
|
| Cerebral Cortex | 1 | 2011 | 126 | 0.090 |
Why?
|
| Magnetoencephalography | 1 | 2009 | 14 | 0.080 |
Why?
|
| Somatosensory Cortex | 1 | 2009 | 26 | 0.080 |
Why?
|
| Pituitary-Adrenal System | 1 | 2009 | 21 | 0.080 |
Why?
|
| Hypothalamo-Hypophyseal System | 1 | 2009 | 31 | 0.080 |
Why?
|
| Blinking | 2 | 2010 | 5 | 0.080 |
Why?
|
| Thermogenesis | 1 | 2008 | 4 | 0.080 |
Why?
|
| Thyroxine | 1 | 2008 | 16 | 0.080 |
Why?
|
| Hyperalgesia | 2 | 2019 | 78 | 0.080 |
Why?
|
| Cerebellum | 1 | 2008 | 26 | 0.080 |
Why?
|
| Brain Mapping | 1 | 2009 | 178 | 0.080 |
Why?
|
| Treatment Outcome | 1 | 2016 | 3306 | 0.080 |
Why?
|
| 3,4-Methylenedioxyamphetamine | 1 | 2007 | 2 | 0.070 |
Why?
|
| Gyrus Cinguli | 1 | 2007 | 22 | 0.070 |
Why?
|
| Extinction, Psychological | 1 | 2007 | 18 | 0.070 |
Why?
|
| Fever | 1 | 2007 | 61 | 0.070 |
Why?
|
| Basal Ganglia | 1 | 2005 | 15 | 0.060 |
Why?
|
| Autoradiography | 1 | 2005 | 45 | 0.060 |
Why?
|
| Sex Factors | 3 | 2012 | 663 | 0.060 |
Why?
|
| Tomography, Emission-Computed | 1 | 2004 | 23 | 0.060 |
Why?
|
| Neostriatum | 1 | 2004 | 22 | 0.060 |
Why?
|
| Tissue Distribution | 1 | 2004 | 61 | 0.060 |
Why?
|
| Quipazine | 1 | 2002 | 1 | 0.050 |
Why?
|
| Serotonin Uptake Inhibitors | 1 | 2002 | 37 | 0.050 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2005 | 835 | 0.050 |
Why?
|
| Homovanillic Acid | 2 | 2012 | 11 | 0.050 |
Why?
|
| Body Temperature | 2 | 2014 | 20 | 0.050 |
Why?
|
| Receptor, Serotonin, 5-HT2A | 1 | 2000 | 3 | 0.050 |
Why?
|
| Prodrugs | 1 | 2020 | 16 | 0.040 |
Why?
|
| Glial Fibrillary Acidic Protein | 1 | 2000 | 41 | 0.040 |
Why?
|
| Hydroxyindoleacetic Acid | 2 | 2010 | 17 | 0.040 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2019 | 62 | 0.040 |
Why?
|
| Injections, Spinal | 1 | 2019 | 108 | 0.040 |
Why?
|
| Pain Threshold | 1 | 2019 | 92 | 0.040 |
Why?
|
| Oxycodone | 1 | 2018 | 6 | 0.040 |
Why?
|
| Structure-Activity Relationship | 1 | 2018 | 80 | 0.040 |
Why?
|
| Drug Design | 1 | 2018 | 43 | 0.040 |
Why?
|
| Morphine | 1 | 2018 | 44 | 0.040 |
Why?
|
| Opioid-Related Disorders | 1 | 2019 | 55 | 0.040 |
Why?
|
| Immunohistochemistry | 1 | 2000 | 538 | 0.040 |
Why?
|
| Appetitive Behavior | 2 | 2008 | 6 | 0.040 |
Why?
|
| Food Preferences | 2 | 2008 | 36 | 0.040 |
Why?
|
| Motor Activity | 2 | 2010 | 325 | 0.040 |
Why?
|
| Pregnancy | 2 | 2010 | 997 | 0.040 |
Why?
|
| Respiratory Insufficiency | 1 | 2016 | 57 | 0.030 |
Why?
|
| Glucose | 1 | 2016 | 174 | 0.030 |
Why?
|
| Animal Experimentation | 1 | 2014 | 5 | 0.030 |
Why?
|
| Species Specificity | 1 | 2012 | 90 | 0.030 |
Why?
|
| Mecamylamine | 1 | 2011 | 11 | 0.020 |
Why?
|
| Nicotinic Antagonists | 1 | 2011 | 17 | 0.020 |
Why?
|
| Evoked Potentials, Somatosensory | 1 | 2009 | 7 | 0.020 |
Why?
|
| Benzylamines | 1 | 2008 | 5 | 0.020 |
Why?
|
| Carbon Isotopes | 1 | 2008 | 9 | 0.020 |
Why?
|
| Nicotine | 1 | 2011 | 171 | 0.020 |
Why?
|
| Fingers | 1 | 2009 | 64 | 0.020 |
Why?
|
| Electric Stimulation | 1 | 2009 | 104 | 0.020 |
Why?
|
| Reaction Time | 1 | 2008 | 117 | 0.020 |
Why?
|
| Injections, Intramuscular | 1 | 2008 | 43 | 0.020 |
Why?
|
| Drug Synergism | 1 | 2008 | 66 | 0.020 |
Why?
|
| Association Learning | 1 | 2007 | 14 | 0.020 |
Why?
|
| Injections, Subcutaneous | 1 | 2007 | 35 | 0.020 |
Why?
|
| Deoxyepinephrine | 1 | 2007 | 2 | 0.020 |
Why?
|
| Serotonin Agents | 1 | 2007 | 5 | 0.020 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2009 | 226 | 0.020 |
Why?
|
| Glucocorticoids | 1 | 2008 | 146 | 0.020 |
Why?
|
| Radiography | 1 | 2007 | 376 | 0.020 |
Why?
|
| United States | 1 | 2014 | 3939 | 0.020 |
Why?
|
| Statistics as Topic | 1 | 2000 | 108 | 0.010 |
Why?
|